On This Page
Helm & Nagel
Tim Filzinger

Tim Filzinger leads press relations, media coordination, and external communications at Helm & Nagel GmbH. He works with German and international trade publications including Springer Professional, BigData-Insider, and IT Daily to place guest articles and thought leadership content. With a deep network of media contacts across Europe, Tim builds and maintains relationships that amplify Helm & Nagel's voice in industry discourse.

Germany's pharmaceutical and medical technology sectors are undergoing unprecedented structural convergence, driven by artificial intelligence's capacity to bridge traditionally isolated domains. Where regulatory frameworks, organizational structures, and technical capabilities once kept these industries operating independently, AI now enables seamless integration of drug discovery, device development, and patient outcome analytics into unified systems.

This convergence manifests across multiple dimensions. Pharmaceutical companies deploy AI to analyze real-world evidence from medical devices, improving both drug design and patient targeting. Medical technology firms transition from hardware vendors selling discrete products to data platform operators generating continuous intelligence. Biotech organizations develop companion diagnostics alongside therapeutics as integrated systems optimized for specific patient populations. These shifts represent systematic structural changes rather than isolated partnerships, reflecting AI's fundamental impact on how healthcare innovation operates.

The pattern extends beyond individual companies. Germany's pharmaceutical-device convergence resembles broader AI integration across industries, where AI serves as the integration layer enabling sectors previously separated by technical or organizational boundaries to function as unified systems. However, Germany's situation carries distinctive characteristics: simultaneous excellence in pharmaceutical R&D, Europe's concentrated medical technology manufacturing base, and substantial AI infrastructure investment create a concentration of convergence-enabling assets unprecedented globally. Realizing this potential requires strategic investment specifically targeting the technical, regulatory, and organizational intersections between these traditionally separate domains.

The Foundation: Three Converging Pillars

Helm & Nagel
CONVERGENCE

Three Pillars Driving Healthcare AI in Germany

  • Pharmaceutical excellence: highest R&D intensity across all German industries at 16.5% of revenue
  • Medical technology: Europe's largest medtech sector transforming from devices to data platforms
  • AI infrastructure: €4.42 billion in European healthtech funding in Q1 2025 alone

Pharmaceutical Excellence: Research Capacity Meets AI Integration

Germany's pharmaceutical sector maintains the highest R&D intensity across all German industries at 16.5% of revenue, ranking as the world's leading exporter of medicinal products. The sector includes major players like Bayer AG (€46.6 billion revenue, 2024), Boehringer Ingelheim (€25.6 billion, 2023), and Merck KGaA (€21.0 billion, 2023).

The transformation manifests in fundamental restructuring of drug discovery processes. Pharmaceutical companies are deploying large language models to process and standardize medical terminology across clinical trials. What previously required extensive manual review now benefits from AI-enabled automation. More significantly, AI is dissolving pharmaceutical development's historical insularity by enabling integration of real-world evidence, genetic data, and device-generated patient information from the earliest drug design stages.

The scale of investment reflects this shift. Boehringer Ingelheim allocated €6.2 billion to R&D in 2024 (23% of net sales). International pharmaceutical companies committed billions to German operations. Eli Lilly's €2.3 billion manufacturing facility in Alzey represents the largest single foreign investment in Germany's pharmaceutical sector in recent years.

Medical Technology Innovation: From Devices to Data Platforms

Germany's medical technology sector is transforming from hardware-centric production to hybrid organizations generating both physical products and data streams. Traditional medical technology operated on a transactional model: manufacture diagnostic equipment, sell to healthcare providers, support through service contracts. AI is transforming this by making the data generated by devices as valuable as the devices themselves.

Consider diagnostic imaging: a CT scanner historically represented a capital equipment purchase valued for image quality and throughput. AI transforms these devices into data generation platforms that continuously learn from every scan performed. The accumulated patterns across thousands of patients enable identification of disease signatures that individual observers cannot detect through superior per-image analysis alone. Detection happens instead through integration across patient populations at previously impossible scales.

This creates new partnership dynamics with pharmaceutical companies. Medical devices generate longitudinal patient data: treatment responses, adherence patterns, and outcome variations that represent precisely what pharmaceutical companies need to design more effective therapies. Companies like Vara (breast cancer screening), Aignostics (pathology diagnostics), and Ada Health (digital health companion) exemplify organizations founded to bridge medical technology capabilities with AI-driven interpretation.

AI Infrastructure: The Integration Layer

Germany's AI healthcare capabilities are distinguished by the combination of technical expertise, regulatory clarity, and domain knowledge spanning both pharmaceutical and medical technology sectors. European healthtech companies secured €4.42 billion in Q1 2025, with healthtech emerging as the most-funded sector. More significant than volume is the shift toward convergence-enabling infrastructure: federated learning systems, interoperability platforms, and regulatory compliance tools navigating pharmaceutical and medical device regulations.

The technical challenge is substantial. Pharmaceutical data includes molecular structures, binding affinities, and toxicology profiles that operate in different domains than medical technology data like imaging characteristics, device measurements, and patient outcomes. AI enables unified analytical frameworks that extract insights from heterogeneous sources that would remain invisible when analyzed separately.

The policy environment reinforces these developments. The Medical Research Act (enacted autumn 2024) streamlines clinical study approvals. AI Regulatory Sandboxes (mandated by August 2026) provide controlled environments for testing products combining pharmaceutical and medical device characteristics.

AI as Catalyst: Dissolving Traditional Boundaries

From Sequential to Integrated Development

Traditional pharmaceutical development followed sequential processes. Identify targets, design molecules, conduct testing, seek approval, then potentially develop companion diagnostics. Medical technology operated in parallel isolation. This separation reflected not merely organizational boundaries but technical limitations in integrating heterogeneous data types.

AI enables simultaneous co-development of diagnostic and therapeutic components. Major pharmaceutical companies like Boehringer now establish partnerships to combine internal preclinical data with real-world data from clinical databases and healthcare systems. AI's capacity to identify patterns across data heterogeneity makes this possible. Pharmaceutical compounds affect patients differently based on comorbidities, genetic profiles, and concurrent treatments. Medical devices capture these variations continuously across large populations. AI systems process this complexity by identifying latent structures in high-dimensional data, creating compounds optimized for specific patient subpopulations with documented response characteristics.

Economic Restructuring Through Companion Diagnostics

The shift described is particularly evident in companion diagnostics, where diagnostic tests and therapeutic agents function as integrated systems. Traditional development required expensive parallel programs. This limited companion diagnostics to blockbuster drugs with large markets. AI transforms these economics by enabling identification of biomarker-therapy relationships across existing datasets, making personalized medicine viable for smaller patient populations previously considered economically unfeasible.

Clinical Trial Transformation

Pharmaceutical companies increasingly integrate medical technology capabilities through partnerships and acquisitions. They deploy AI-powered radiology platforms, automated monitoring systems, and digital biomarkers for trial optimization. Major companies like Sanofi, Bayer, and AstraZeneca leverage external AI specialists rather than building entirely in-house. This reflects recognition that combining pharmaceutical development with medical technology measurement systems can accelerate research, even when regulatory frameworks treat these as distinct categories.

This integration enables adaptive trial designs where protocol modifications, patient monitoring, and outcome predictions operate as coordinated systems. Adaptive trial designs reduce time and cost required to identify optimal approaches. Adaptive designs allow prospectively planned modifications to trial parameters including sample size, dosing, and patient selection based on interim analyses while maintaining statistical validity. The shift from rigid, pre-specified protocols to adaptive frameworks represents a significant evolution in how pharmaceutical research operates. Regulatory bodies like the FDA now provide guidance to support these approaches.

The Implementation Challenge: Building Infrastructure

The outlined vision requires solving fundamental technical and organizational challenges that most organizations underestimate. Consider the practical reality: a pharmaceutical company pursuing integrated drug-device development must extract structured information from clinical study reports spanning thousands of pages. They must process regulatory documentation in multiple languages and formats, real-world evidence from deployed medical devices, patient outcome data from electronic health records, and scientific literature across decades of research.

Beyond data challenges, convergence requires addressing:

Regulatory complexity: Products combining pharmaceutical and device characteristics navigate dual regulatory pathways. The EU AI Act adds additional compliance layers for AI-enabled systems. Organizations need expertise spanning EMA pharmaceutical guidelines, MDR medical device requirements, and AI-specific regulations. These were traditionally managed by separate teams with limited cross-training.

Organizational silos: Pharmaceutical and medical technology divisions within the same company often operate as separate entities. They have distinct cultures, incentive structures, and strategic priorities. Breaking these silos requires executive commitment and structural reorganization that many organizations resist, particularly when shifting business models and revenue recognition approaches.

Intellectual property complexity: Convergence products combine pharmaceutical patents, device patents, software copyrights, and AI training data rights. Navigating this IP landscape, particularly in collaborative projects, requires sophisticated legal frameworks that traditional licensing agreements don't address.

Reimbursement uncertainty: Healthcare systems lack established pathways for pricing and reimbursing integrated pharma-device products. Banks face analogous challenges when integrating insurance and banking products. A companion diagnostic bundled with a therapeutic faces questions about separate versus combined reimbursement. This creates market access challenges that delay adoption.

Addressing these multifaceted challenges requires coordinated action across technical, regulatory, organizational, and commercial domains. Organizations that develop systematic approaches rather than treating it as isolated partnerships create sustainable competitive advantages.

Strategic Implications: The Convergence Opportunity

Germany's position appears distinctive because it maintains top-tier capabilities across all three sectors simultaneously. The United States leads in AI capabilities and maintains comparable pharmaceutical infrastructure, but it lacks Germany's concentrated medical technology sector. Switzerland hosts pharmaceutical giants but operates at smaller scale. China expands rapidly but faces regulatory uncertainty and limited Western market acceptance in healthcare technologies.

Germany uniquely combines established pharmaceutical infrastructure, Europe's largest medical technology sector, substantial AI investment, and predictable regulatory frameworks under EU AI Act implementation.

The Critical Window: 2025-2026

The opportunity operates within a defined temporal window. EU Apply AI funding opens for applications in December 2025. AI Regulatory Sandboxes are required to be operational by August 2026. Early-stage projects initiated during this period may benefit from establishing technical standards and regulatory precedents ahead of competitors. Industry patterns suggest that by 2027-2028, market consolidation could accelerate as large companies seek to acquire successful convergence ventures.

Strategic positioning decisions made in 2025-2026 are likely to substantially influence competitive positions through the decade.

Conclusion

The convergence of pharmaceutical development, medical technology, and artificial intelligence represents a structural transformation in healthcare innovation. Germany's simultaneous strength across all three domains creates opportunities that few other geographies can match in breadth and depth. Research from Tempus AI's collaboration with Boehringer Ingelheim demonstrates how AI-driven text analysis can extract patterns across heterogeneous clinical datasets.

However, the strategies remain theoretical without systematic approaches to the technical, regulatory, organizational, and commercial challenges outlined here. Organizations pursuing convergence must build infrastructure capable of extracting, structuring, and integrating information from heterogeneous sources like clinical documentation, regulatory submissions, device data streams, and scientific literature.

These sectoral strengths must be actively connected through strategic investment in integration infrastructure, collaborative projects, and collaboration-specific policy frameworks. The alternative is maintaining separate industries that individually remain strong but collectively miss opportunities to capitalize on integration advantages being pursued elsewhere.

The strategic opportunity is evident: invest in the intersections between sectors during the 2025-2026 window when funding, regulatory frameworks, and market momentum align. The risk is watching convergence leadership emerge elsewhere while German sectoral excellence remains fragmented. The technical capabilities exist. The market opportunity is substantial. The regulatory environment provides clarity. What remains is strategic action focused specifically on convergence.

The convergence opportunity depends on solving complex data integration challenges. Helm & Nagel GmbH's AI solutions extract structured information from thousands of pages of clinical documentation, regulatory files, and scientific literature, turning heterogeneous data sources into actionable insights. Let's discuss how we can support your strategy.

References

  1. European Commission. (2025, July 18). Guidelines on the scope of obligations for providers of general-purpose AI models under the AI Act. Retrieved from https://digital-strategy.ec.europa.eu/en/library/guidelines-scope-obligations-providers-general-purpose-ai-models-under-ai-act
  2. Germany Trade & Invest. (2024). The Pharmaceutical Industry in Germany. Retrieved from https://www.gtai.de/en/invest/industries/healthcare-market-germany/pharmaceutical-industry
  3. Powtech Technopharm. (2024, February 8). Europe's pharmaceutical industry at risk? What Trump's policy means for 2025 and beyond. Retrieved from https://www.powtech-technopharm.com/en/industry-insights/2024/article/pharmaceutical-industry-facing-challenges-and-opportunities-in-2024
  4. Tracxn. (2025, September). Top startups in Native AI in Healthcare in Germany. Retrieved from https://tracxn.com/d/explore/native-ai-in-healthcare-startups-in-germany/__oWTah7TQDmqbj3wK5hPiOvF9G23o29Q9iv-GG-ut0VY/companies
  5. EU-Startups. (2025, May 30). AI meets Health: 10 promising European startups leading the change in 2025. Retrieved from https://www.eu-startups.com/2025/05/ai-meets-healthtech-10-promising-european-startups-leading-the-change-in-2025/
  6. HLTH. (2025, May 15). Boehringer Ingelheim Enhances Oncology Research Through Tempus AI Partnership. Retrieved from https://hlth.com/insights/news/boehringer-ingelheim-enhances-oncology-research-through-tempus-ai-partnership-2025-05-15
  7. Boehringer Ingelheim. (2024, April 16). Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline. Retrieved from https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline
  8. Bayer Global. (n.d.). Delivering on the promise of artificial intelligence. Retrieved from https://www.bayer.com/en/pharma/artificial-intelligence
  9. Bayer AG. (2024, March 5). Bayer Annual Report 2023. Retrieved from https://www.bayer.com/sites/default/files/2024-03/bayer-annual-report-2023.pdf
  10. Boehringer Ingelheim. (2024). 2023 Highlights: Life forward. Retrieved from https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf
  11. Merck KGaA, Darmstadt, Germany. (2024, March 7). Financial results fiscal 2023. Retrieved from https://www.emdgroup.com/en/news/q4-2023-07-03-2024.html
  12. Eli Lilly and Company. (2023, November 17). Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lilly-expand-injectable-manufacturing-capacity-planned-25
  13. Tech.eu. (2025, April 22). Europe's healthtech and AI startups raise $13.9B in Q1 as global investors return. Retrieved from https://tech.eu/2025/04/22/europes-healthtech-and-ai-startups-raise-139b-in-q1-as-global-investors-return/
  14. Healthcare.digital. (2025, July 18). European HealthTech, Digital Health and Healthcare AI Exits in 2025: A Mid-Year Analysis and Outlook. Retrieved from https://www.healthcare.digital/single-post/european-healthtech-digital-health-and-healthcare-ai-exits-in-2025-a-mid-year-analysis-and-outlook
  15. Altios. (2025, February 18). The Pharmaceutical Industry in Germany: Growth, Investment, and Market Potential. Retrieved from https://altios.com/publication/the-pharmaceutical-industry-in-germany/
  16. TradeImeX. (2025). Germany Pharmaceutical Exports Data 2025: Why Germany Leads the World in Pharmaceutical Exports? Retrieved from https://tradeimex.in/blogs/germany-pharmaceutical-exports-data-2025-top-exporter
  17. Tempus AI, Inc. (2025, May 14). Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline. Retrieved from https://investors.tempus.com/news-releases/news-release-details/tempus-enters-multi-year-strategic-collaboration-boehringer